ARTICLE | Company News
Lupin launches IPR challenge against Vimovo
August 21, 2015 1:09 AM UTC
Lupin Ltd. (NSE:LUPIN; BSE:500257) filed three inter partes review (IPR) petitions with the U.S. Patent and Trademark Office challenging patents from Pozen Inc. (NASDAQ:POZN) covering Vimovo naproxen/esomeprazole. Lupin alleged that several claims from U.S. Patent Nos. 8,852,636; 8,858,996; and 8,865,190 are unpatentable on the grounds of obviousness.
The '636 and '996 patents both cover Vimovo's composition and method of use, and both expire in 2022. There are 11 Orange Book-listed patents covering Vimovo. One patent expired earlier this year and the last expires in 2031. ...